325 related articles for article (PubMed ID: 32696064)
1. Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis.
Cruz-Machado AR; Rodrigues-Manica S; Silva JL; Alho I; Coelho C; Duarte J; Florêncio C; Pimentel-Santos FM; Tavares-Costa J; Vieira-Sousa E
Rheumatology (Oxford); 2020 Nov; 59(11):3158-3171. PubMed ID: 32696064
[TBL] [Abstract][Full Text] [Related]
2. Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study.
Sieper J; Landewé R; Magrey M; Anderson JK; Zhong S; Wang X; Lertratanakul A
RMD Open; 2019; 5(1):e000917. PubMed ID: 31245052
[TBL] [Abstract][Full Text] [Related]
3. Biologic disease-modifying anti-rheumatic drugs and patient-reported outcomes in axial SpA: a systematic review and a call for action.
Rodrigues-Manica S; Silva J; Cruz-Machado R; Coelho C; Duarte J; Vieira-Sousa E; Tavares-Costa J; Pimentel-Santos FM
Clin Rheumatol; 2021 Jan; 40(1):33-41. PubMed ID: 32533340
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
5. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
[TBL] [Abstract][Full Text] [Related]
6. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
Malaviya AN; Kalyani A; Rawat R; Gogia SB
Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
[TBL] [Abstract][Full Text] [Related]
7. Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies.
Baraliakos X; Van den Bosch F; Machado PM; Gensler LS; Marzo-Ortega H; Sherif B; Quebe-Fehling E; Porter B; Gaillez C; Deodhar A
Rheumatol Ther; 2021 Mar; 8(1):273-288. PubMed ID: 33351179
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study.
Lubrano E; Massimo Perrotta F; Manara M; D'Angelo S; Addimanda O; Ramonda R; Punzi L; Olivieri I; Salvarani C; Marchesoni A
J Rheumatol; 2016 Aug; 43(8):1541-6. PubMed ID: 27252428
[TBL] [Abstract][Full Text] [Related]
9. Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.
Sieper J; Rudwaleit M; Lenaerts J; Wollenhaupt J; Myasoutova L; Park SH; Song YW; Yao R; Huyck S; Govoni M; Chitkara D; Vastesaeger N
Rheumatology (Oxford); 2016 Nov; 55(11):1946-1953. PubMed ID: 27411482
[TBL] [Abstract][Full Text] [Related]
10. Predictors of remission in people with axial spondyloarthritis: A systematic literature review.
Pinto AS; Farisogullari B; Machado PM
Semin Arthritis Rheum; 2022 Oct; 56():152078. PubMed ID: 35944350
[TBL] [Abstract][Full Text] [Related]
11. Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study.
Lubrano E; Perrotta FM; Marchesoni A; D'Angelo S; Ramonda R; Addimanda O; Olivieri I; Punzi L; Salvarani C
J Rheumatol; 2015 Feb; 42(2):258-63. PubMed ID: 25512483
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of TNF-α Inhibitors in the Treatment of nr-axSpA: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials.
Shentu H; Sha S; He Y; He M; Dong N; Huang Z; Lai H; Chen M; Huang J; Huang X
Int Arch Allergy Immunol; 2024; 185(6):590-599. PubMed ID: 38432201
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.
Ortolan A; Webers C; Sepriano A; Falzon L; Baraliakos X; Landewé RB; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):142-152. PubMed ID: 36261247
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis.
Deodhar A; Machado PM; Mørup M; Taieb V; Willems D; Orme M; Pritchett D; Gensler LS
Rheumatology (Oxford); 2024 May; 63(5):1195-1205. PubMed ID: 37947318
[TBL] [Abstract][Full Text] [Related]
15. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.
Ørnbjerg LM; Brahe CH; Askling J; Ciurea A; Mann H; Onen F; Kristianslund EK; Nordström D; Santos MJ; Codreanu C; Gómez-Reino J; Rotar Z; Gudbjornsson B; Di Giuseppe D; Nissen MJ; Pavelka K; Birlik M; Kvien T; Eklund KK; Barcelos A; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Loft AG; van der Horst-Bruinsma I; Jones G; Iannone F; Hyldstrup L; Krogh NS; Hetland ML; Østergaard M
Ann Rheum Dis; 2019 Nov; 78(11):1536-1544. PubMed ID: 31431486
[TBL] [Abstract][Full Text] [Related]
16. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
17. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.
Ramiro S; Nikiphorou E; Sepriano A; Ortolan A; Webers C; Baraliakos X; Landewé RBM; Van den Bosch FE; Boteva B; Bremander A; Carron P; Ciurea A; van Gaalen FA; Géher P; Gensler L; Hermann J; de Hooge M; Husakova M; Kiltz U; López-Medina C; Machado PM; Marzo-Ortega H; Molto A; Navarro-Compán V; Nissen MJ; Pimentel-Santos FM; Poddubnyy D; Proft F; Rudwaleit M; Telkman M; Zhao SS; Ziade N; van der Heijde D
Ann Rheum Dis; 2023 Jan; 82(1):19-34. PubMed ID: 36270658
[TBL] [Abstract][Full Text] [Related]
18. Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials.
Kiltz U; van der Heijde D; Boonen A; Gensler LS; Gibble TH; Guo J; Carlier H; Braun J
J Rheumatol; 2023 Jun; 50(6):754-762. PubMed ID: 36725056
[TBL] [Abstract][Full Text] [Related]
19. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
Braun J; Kiltz U; Baraliakos X
Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.
Poddubnyy D; Gensler LS
Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):807-18. PubMed ID: 25488786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
